Adar Poonawalla commits 100 million doses of vaccines every year to Biocon Biologics
The Hindu
Biocon Biologics will offer 15% stake to Serum Institute Life Sciences
Biocon Biologics Limited (BBL) will offer approximately 15% stake to Serum Institute Life Sciences Private Limited (SILS) at a post-money valuation of $4.9 billion in exchange for committed access to 100 million doses of vaccines per annum for 15 years, primarily from SILS’s upcoming vaccine facility in Pune with commercialisation rights of the SILS vaccine portfolio, including COVID-19 vaccines, for global markets.
Biocon Biologics Limited (BBL) is a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS) is a subsidiary of Serum Institute of India.
More Related News













